Cellectar Biosciences is reporting patients in a recent clinical trial of its cancer therapy medication are surviving longer.
The first four study groups of the Madison company’s ongoing Phase 1 clinical trial included 15 patients who had been previously treated with five lines of therapy on average. Each patient in those four study groups received a single 30-minute infusion of CLR 131, Cellectar’s cancer treatment drug.
Results from that research show those patients had a median overall survival rate of 22 months, which CEO and President James Caruso says is “very encouraging.”
“We believe extending [survival] with a more patient-friendly dosing regimen provides both a distinctive product profile and the potential to provide beneficial patient outcomes even in later lines of therapy,” Caruso said.
It’s noted in the release that CLR 131 hasn’t been directly compared against other therapies. But other similar studies have previously achieved median overall survival rates of up to 12 months for patients in the “heavily pretreated” population.
“These are patients with limited therapeutic options and, unfortunately, face poor prognoses,” Caruso said.
He says the treatment, which can be delivered in one or two doses, is less intrusive than treatments that must be administered overtime at regular intervals.
See more at WisBusiness.com.
